ReviewCellular and molecular life sciences : CMLS2018
Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.
Review in Cellular and molecular life sciences : CMLS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 92 citations in OpenAlex.
- Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism.Biology of sex differences · 2021Trial
- Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis.Clinical and molecular hepatology · 2025Review
- Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation.Biomedicines · 2025Review
- Alleviating effect ofFrontiers in nutrition · 2025Article
- Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD.Frontiers in pharmacology · 2025Review
- Ginsenoside Rg1 Alleviates Blood-Milk Barrier Disruption in Subclinical Bovine Mastitis by Regulating Oxidative Stress-Induced Excessive Autophagy.Antioxidants (Basel, Switzerland) · 2024Article
- ASPP2 deficiency attenuates lipid accumulation through the PPARγ pathway in alcoholic liver injury.Cell biology and toxicology · 2024Article
- Alterations in the Intestinal Microbiome and Metabolic Profile of British Shorthair Kittens Fed with Milk Replacer.Animals : an open access journal from MDPI · 2024Article
- Article
- Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway.Journal of translational medicine · 2024Article
- Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease.Signal transduction and targeted therapy · 2024Article
- Effects of riboflavin deficiency and high dietary fat on hepatic lipid accumulation: a synergetic action in the development of non-alcoholic fatty liver disease.Nutrition & metabolism · 2024Article
- Ethanol extract ofFrontiers in pharmacology · 2024Article
- Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- Natural Drugs: A New Direction for the Prevention and Treatment of Diabetes.Molecules (Basel, Switzerland) · 2023Review
- Epigenetic Histone Methylation of PPARγ and CPT1A Signaling Contributes to Betahistine Preventing Olanzapine-Induced Dyslipidemia.International journal of molecular sciences · 2023Article
- Vitamin D improves hepatic steatosis in NAFLDFrontiers in endocrinology · 2023Article
- Therapeutic Effects ofAntioxidants (Basel, Switzerland) · 2022Article
- Therapies for non-alcoholic fatty liver disease: A 2022 update.World journal of hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overweight and obesity have been identified as the most important risk factors for many diseases, including cardiovascular disease, type 2 diabetes and lipid disorders, such as non-alcoholic fatty liver disease (NAFLD). The metabolic changes associated with obesity are grouped to define metabolic syndrome, which is one of the main causes of morbidity and mortality in industrialized countries. NAFLD is considered to be the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver diseases worldwide. Inflammation plays an important role in the development of numerous liver diseases, contributing to the progression to more severe stages, such as non-alcoholic steatohepatitis and hepatocellular carcinoma. Peroxisome proliferator-activated receptors (PPARs) are binder-activated nuclear receptors that are involved in the transcriptional regulation of lipid metabolism, energy balance, inflammation and atherosclerosis. Three isotypes are known: PPAR-α, PPARδ/β and PPAR-γ. These isotypes play different roles in diverse tissues and cells, including the inflammatory process. In this review, we discuss current knowledge on the role PPARs in the hepatic inflammatory process involved in NAFLD as well as new pharmacological strategies that target PPARs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.